Published in Autoimmun Rev on May 06, 2006
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest (2007) 1.45
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One (2011) 1.14
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol (2013) 1.05
Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One (2012) 1.01
Vitiligo--part 1. An Bras Dermatol (2014) 0.96
Oral manifestations of vitiligo. Indian J Dermatol (2015) 0.93
Nonsegmental vitiligo and autoimmune mechanism. Dermatol Res Pract (2011) 0.89
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88
Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. PLoS One (2010) 0.86
Gene expression signature for spontaneous cancer regression in melanoma pigs. Neoplasia (2008) 0.86
Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res (2014) 0.78
Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients' autologous melanocytes transplantation efficiency. PLoS One (2013) 0.76
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. PLoS One (2015) 0.76
Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo. Genes Immun (2015) 0.75
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development (1992) 2.05
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70
Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 1.64
On the etiology of contact/occupational vitiligo. Pigment Cell Res (2004) 1.55
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol (2001) 1.44
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41
Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest (2000) 1.39
MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem (2005) 1.36
Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35
Subcellular distribution of tyrosinase and tyrosinase-related protein-1: implications for melanosomal biogenesis. J Invest Dermatol (1993) 1.29
Stress proteins and initiation of immune response: chaperokine activity of hsp72. Exerc Immunol Rev (2005) 1.24
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol (1993) 1.19
MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res (2005) 1.18
Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol (1991) 1.15
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest (2002) 1.15
Reversal of developmental restrictions in neural crest lineages: transition from Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci U S A (2003) 1.15
Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol (1997) 1.10
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res (2006) 1.09
A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol (1993) 1.08
Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol (2005) 1.07
Ethnic skin disorders overview. J Am Acad Dermatol (2003) 1.05
Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol (1991) 1.04
Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol (1988) 1.02
A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol (2001) 1.00
Stigma experience in skin disorders: an Indian perspective. Dermatol Clin (2005) 0.98
In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol (1995) 0.95
What patients with vitiligo believe about their condition. Int J Dermatol (2004) 0.95
Phagocytosis by normal human melanocytes in vitro. Exp Cell Res (1993) 0.95
Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit Rev Immunol (2005) 0.94
Late onset vitiligo: a study of 182 patients. Int J Dermatol (2005) 0.92
Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res (1995) 0.91
Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch Dermatol Res (1994) 0.86
Psoralen plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Clin Exp Dermatol (2004) 0.85
Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol (1994) 0.84
Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol (2000) 0.84
Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin. Br J Dermatol (2003) 0.82
Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur J Immunol (2005) 0.81
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem (2008) 1.54
Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol (2004) 1.54
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother (2004) 1.54
In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50
A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50
Genome-wide association analysis with gray matter volume as a quantitative phenotype in first-episode treatment-naïve patients with schizophrenia. PLoS One (2013) 1.47
Progression of undiagnosed cutaneous T-cell lymphoma during efalizumab therapy. Arch Dermatol (2009) 1.46
SiRNA delivery with exosome nanoparticles. Nat Biotechnol (2011) 1.46
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41
Spanish-speaking patient health educational preferences. Arch Dermatol (2011) 1.39
Medical student detection of melanoma: clinical skills. Arch Dermatol (2010) 1.39
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol (2003) 1.38
Strain and virulence diversity in the mouse pathogen Chlamydia muridarum. Infect Immun (2009) 1.36
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A (2010) 1.36
Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp (2011) 1.32
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol (2003) 1.32
Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol (2007) 1.22
Notch signaling regulates mouse and human Th17 differentiation. J Immunol (2011) 1.21
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11
Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol (2003) 1.09
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res (2006) 1.09
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia. Am J Psychiatry (2013) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One (2010) 1.03
Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res (2009) 1.03
Functional defects of dendritic cells in patients with CD40 deficiency. Blood (2003) 1.02
Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc (2004) 1.01
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol (2008) 0.98
First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res (2010) 0.96
Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog (2010) 0.96
Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95
Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol (2006) 0.95
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res (2003) 0.93
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92
Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res (2011) 0.92
Assessment of white matter abnormalities in paranoid schizophrenia and bipolar mania patients. Psychiatry Res (2011) 0.92
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol (2013) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother (2010) 0.90
Immunosuppression may be present within condyloma acuminata. J Am Acad Dermatol (2008) 0.90
Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89
Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Cancer Res (2006) 0.89
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology (2006) 0.89
A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol (2012) 0.89
The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res (2013) 0.89
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88
T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int Rev Immunol (2006) 0.88
HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88
Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87
Hydrostatic pressures promote initial osteodifferentiation with ERK1/2 not p38 MAPK signaling involved. J Cell Biochem (2009) 0.86
Leprosy-specific B-cells within cellular infiltrates in active leprosy lesions. Hum Pathol (2007) 0.85
Skin irritants and contact sensitizers induce Langerhans cell migration and maturation at irritant concentration. Exp Dermatol (2006) 0.85
Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother (2007) 0.85
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother (2015) 0.84
M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathol (2015) 0.84
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother (2008) 0.83
Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res (2011) 0.83
Subtoxic concentrations of allergenic haptens induce LC migration and maturation in a human organotypic skin explant culture model: a novel method for identifying potential contact allergens. Exp Dermatol (2006) 0.83
CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunol Immunother (2010) 0.83